(NYSE: RDY) Dr Reddys Laboratories's forecast annual revenue growth rate of 6.43% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.62%.
Dr Reddys Laboratories's revenue in 2025 is $3,350,504,080.On average, 3 Wall Street analysts forecast RDY's revenue for 2026 to be $3,261,232,875,268, with the lowest RDY revenue forecast at $3,163,825,187,476, and the highest RDY revenue forecast at $3,409,289,924,982.
In 2027, RDY is forecast to generate $3,165,518,392,876 in revenue, with the lowest revenue forecast at $3,054,951,246,171 and the highest revenue forecast at $3,294,218,685,095.